FDA: Class I Recall of 48 Medtronic ICDs, CRT-Ds


February 27, 2018

The US Food and Drug Administration (FDA) has declared a class I recall of a limited number of implantable defibrillators from Medtronic, including some with biventricular pacing capability, because of a manufacturing defect.

"This defect causes an out-of-specification gas mixture inside the device" that could cause it to fail to deliver high- or low-voltage therapy (that is, shocks or pacing), according to the agency.

The recall applies to 48 individual devices, listed by their serial numbers, that include Medtronic Evera and Visia implantable cardioverter-defibrillators (ICDs) and Amplia, Claria, Compia, and Viva cardiac resynchronization therapy-defibrillators (CRT-Ds).

On January 22, Medtronic instructed clinicians to "consider prophylactic device replacement for patients who have been implanted with one of the affected devices."

Follow Steve Stiles on Twitter: @SteveStiles2. For more from theheart.org | Medscape Cardiology, follow us on Twitter and Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.